<ul>
<li>可能還有時間投資這三家熱門生物科技公司</li>
</ul>
<p>Sana Biotechnology, Inc. (NASDAQ:SANA - 免費報告) - HC Wainwright 的股票研究分析師在 4 月 14 日星期二發佈的研究報告中上調了對 Sana Biotechnology 2026 年第二季度每股收益 (EPS) 的預期。HC Wainwright 分析師 E. Bodnar 現在預測該公司本季度每股收益為（$0.12），高於之前的預測（$0.13）。HC Wainwright 對該股票給予 &#34;買入&#34; 評級，目標價為 $7.00。市場普遍預期 Sana Biotechnology 當前全年的每股收益為（$1.16）。HC Wainwright 還對 Sana Biotechnology 2026 財年的每股收益預期為（$0.52），2027 財年為（$0.58），2028 財年為（$0.63），2029 財年為（$0.65）。</p>
<p>獲取 <strong>Sana Biotechnology</strong> 警報：</p>
<p>Sana Biotechnology (NASDAQ:SANA - 獲取免費報告) 最近在 3 月 3 日星期二發佈了其財報。該公司報告本季度每股收益為（$0.16），低於市場普遍預期的（$0.13），差額為（$0.03）。</p>
<p>其他分析師也對該公司發佈了報告。Zacks Research 在 3 月 3 日星期二的報告中將 Sana Biotechnology 的評級從 &#34;強烈買入&#34; 下調至 &#34;持有&#34;。Wedbush 在星期二的報告中將 Sana Biotechnology 的目標價從 $6.00 上調至 $7.00，並給予該公司 &#34;跑贏大盤&#34; 的評級。Weiss Ratings 在星期二的報告中重申了對 Sana Biotechnology 股票的 &#34;賣出（d-）&#34; 評級。美國銀行在 1 月 6 日星期二的報告中將 Sana Biotechnology 的目標價從 $6.00 上調至 $7.00，並給予該公司 &#34;買入&#34; 評級。最後，華爾街 Zen 在 2 月 7 日星期六的報告中將 Sana Biotechnology 的評級從 &#34;持有&#34; 下調至 &#34;賣出&#34;。六位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Sana Biotechnology 當前的平均評級為 &#34;適度買入&#34;，共識目標價為 $8.20。</p>
<p><strong>查看我們最新的 Sana Biotechnology 股票報告</strong></p>
<h2>Sana Biotechnology 股價下跌 1.1%</h2>
<p>SANA 股票在星期四開盤價為 $3.44。該公司的 50 日移動平均價格為 $3.48，200 日移動平均價格為 $4.13。該公司的市值為 $9.1803 億，市盈率為 -3.55，貝塔值為 2.06。Sana Biotechnology 的一年低點為 $1.53，一年高點為 $6.55。</p>
<h2>對 Sana Biotechnology 的對沖基金看法</h2>
<p>機構投資者最近買入和賣出了該公司的股票。洛克菲勒資本管理公司在第四季度將其在 Sana Biotechnology 的持股增加了 74.3%。洛克菲勒資本管理公司現在擁有 9,588 股該公司的股票，價值 $39,000，此前在上個季度又購買了 4,088 股。TD Waterhouse Canada Inc. 在第三季度獲得了 Sana Biotechnology 的新頭寸，價值約 $37,000。LRI Investments LLC 在第四季度獲得了 Sana Biotechnology 的新頭寸，價值約 $41,000。Jacobi Capital Management LLC 在第四季度獲得了 Sana Biotechnology 的新頭寸，價值約 $41,000。最後，Mercer Global Advisors Inc. ADV 在第三季度獲得了 Sana Biotechnology 的新頭寸，價值約 $36,000。機構投資者和對沖基金持有該公司 88.23% 的股票。</p>
<h2>Sana Biotechnology 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Sana Biotechnology 是一家臨牀階段的生物製藥公司，專注於開發工程細胞作為藥物，旨在治療廣泛的疾病。該公司應用先進的基因編輯和基因傳遞技術，創造用於腫瘤學、遺傳疾病和其他嚴重疾病的下一代細胞治療產品。通過利用體外和體內的方法，Sana 旨在修復或替換受損細胞，恢復健康的組織功能。</p>
<p>該公司的核心平台整合了專有的基因寫入能力以及已建立的基因編輯工具，如 CRISPR–Cas9。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Sana Biotechnology</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ"/></p>
<p><em>此即時新聞警報由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Sana Biotechnology 嗎？</h2>
<p>在你考慮投資 Sana Biotechnology 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Sana Biotechnology 並不在名單上。</p>
<p>雖然 Sana Biotechnology 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>查看這五隻股票</p>

SANA

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

2 倍做多納斯達克生物技術 ETF - ProShares

IBBQ

標普生物技術 3 倍做多 - Direxion

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

動態生物技術與基因組 ETF - Invesco

<p>HC Wainwright 將 Sana Biotechnology (NASDAQ:SANA) 2026 年第二季度每股收益預期從（$0.13）上調至（$0.12），維持 “買入” 評級，目標價為 $7.00。全年每股收益的共識預期為（$1.16）。其他分析師的評級各異，其中六位給予買入評級，一位給予賣出評級。Sana 的股票開盤價為 $3.44，市值為 $9.1803 億。該公司專注於針對各種疾病的工程細胞療法，利用先進的基因編輯技術</p>

<ul>
<li>There May Still Be Time to Get in on These 3 Trending Biotechs</li>
</ul>
<div class="lb-trans"><ul>
<li>可能還有時間投資這三家熱門生物科技公司</li>
</ul>
</div><p>Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) - Equities research analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Sana Biotechnology in a research note issued on Tuesday, April 14th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their previous estimate of ($0.13). HC Wainwright has a &#34;Buy&#34; rating and a $7.00 price objective on the stock. The consensus estimate for Sana Biotechnology's current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology's FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.63) EPS and FY2029 earnings at ($0.65) EPS.</p>
<div class="lb-trans"><p>Sana Biotechnology, Inc. (NASDAQ:SANA - 免費報告) - HC Wainwright 的股票研究分析師在 4 月 14 日星期二發佈的研究報告中上調了對 Sana Biotechnology 2026 年第二季度每股收益 (EPS) 的預期。HC Wainwright 分析師 E. Bodnar 現在預測該公司本季度每股收益為（$0.12），高於之前的預測（$0.13）。HC Wainwright 對該股票給予 &#34;買入&#34; 評級，目標價為 $7.00。市場普遍預期 Sana Biotechnology 當前全年的每股收益為（$1.16）。HC Wainwright 還對 Sana Biotechnology 2026 財年的每股收益預期為（$0.52），2027 財年為（$0.58），2028 財年為（$0.63），2029 財年為（$0.65）。</p>
</div><p>Get <strong>Sana Biotechnology</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sana Biotechnology</strong> 警報：</p>
</div><p>Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03).</p>
<div class="lb-trans"><p>Sana Biotechnology (NASDAQ:SANA - 獲取免費報告) 最近在 3 月 3 日星期二發佈了其財報。該公司報告本季度每股收益為（$0.16），低於市場普遍預期的（$0.13），差額為（$0.03）。</p>
</div><p>Other analysts have also issued reports about the company. Zacks Research lowered Sana Biotechnology from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, March 3rd. Wedbush boosted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Sana Biotechnology in a report on Tuesday. Bank of America boosted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, January 6th. Finally, Wall Street Zen lowered Sana Biotechnology from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, February 7th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Sana Biotechnology currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $8.20.</p>
<div class="lb-trans"><p>其他分析師也對該公司發佈了報告。Zacks Research 在 3 月 3 日星期二的報告中將 Sana Biotechnology 的評級從 &#34;強烈買入&#34; 下調至 &#34;持有&#34;。Wedbush 在星期二的報告中將 Sana Biotechnology 的目標價從 $6.00 上調至 $7.00，並給予該公司 &#34;跑贏大盤&#34; 的評級。Weiss Ratings 在星期二的報告中重申了對 Sana Biotechnology 股票的 &#34;賣出（d-）&#34; 評級。美國銀行在 1 月 6 日星期二的報告中將 Sana Biotechnology 的目標價從 $6.00 上調至 $7.00，並給予該公司 &#34;買入&#34; 評級。最後，華爾街 Zen 在 2 月 7 日星期六的報告中將 Sana Biotechnology 的評級從 &#34;持有&#34; 下調至 &#34;賣出&#34;。六位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Sana Biotechnology 當前的平均評級為 &#34;適度買入&#34;，共識目標價為 $8.20。</p>
</div><p><strong>Check Out Our Latest Stock Report on Sana Biotechnology</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Sana Biotechnology 股票報告</strong></p>
</div><h2>Sana Biotechnology Trading Down 1.1%</h2>
<div class="lb-trans"><h2>Sana Biotechnology 股價下跌 1.1%</h2>
</div><p>SANA stock opened at $3.44 on Thursday. The business's 50-day moving average price is $3.48 and its two-hundred day moving average price is $4.13. The firm has a market cap of $918.03 million, a PE ratio of -3.55 and a beta of 2.06. Sana Biotechnology has a 1-year low of $1.53 and a 1-year high of $6.55.</p>
<div class="lb-trans"><p>SANA 股票在星期四開盤價為 $3.44。該公司的 50 日移動平均價格為 $3.48，200 日移動平均價格為 $4.13。該公司的市值為 $9.1803 億，市盈率為 -3.55，貝塔值為 2.06。Sana Biotechnology 的一年低點為 $1.53，一年高點為 $6.55。</p>
</div><h2>Hedge Funds Weigh In On Sana Biotechnology</h2>
<div class="lb-trans"><h2>對 Sana Biotechnology 的對沖基金看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. increased its position in Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock worth $39,000 after buying an additional 4,088 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in Sana Biotechnology during the third quarter worth approximately $37,000. LRI Investments LLC acquired a new position in Sana Biotechnology during the fourth quarter worth approximately $41,000. Jacobi Capital Management LLC acquired a new position in Sana Biotechnology during the fourth quarter worth approximately $41,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Sana Biotechnology during the third quarter worth approximately $36,000. Institutional investors and hedge funds own 88.23% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近買入和賣出了該公司的股票。洛克菲勒資本管理公司在第四季度將其在 Sana Biotechnology 的持股增加了 74.3%。洛克菲勒資本管理公司現在擁有 9,588 股該公司的股票，價值 $39,000，此前在上個季度又購買了 4,088 股。TD Waterhouse Canada Inc. 在第三季度獲得了 Sana Biotechnology 的新頭寸，價值約 $37,000。LRI Investments LLC 在第四季度獲得了 Sana Biotechnology 的新頭寸，價值約 $41,000。Jacobi Capital Management LLC 在第四季度獲得了 Sana Biotechnology 的新頭寸，價值約 $41,000。最後，Mercer Global Advisors Inc. ADV 在第三季度獲得了 Sana Biotechnology 的新頭寸，價值約 $36,000。機構投資者和對沖基金持有該公司 88.23% 的股票。</p>
</div><h2>Sana Biotechnology Company Profile</h2>
<div class="lb-trans"><h2>Sana Biotechnology 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.</p>
<div class="lb-trans"><p>Sana Biotechnology 是一家臨牀階段的生物製藥公司，專注於開發工程細胞作為藥物，旨在治療廣泛的疾病。該公司應用先進的基因編輯和基因傳遞技術，創造用於腫瘤學、遺傳疾病和其他嚴重疾病的下一代細胞治療產品。通過利用體外和體內的方法，Sana 旨在修復或替換受損細胞，恢復健康的組織功能。</p>
</div><p>The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.</p>
<div class="lb-trans"><p>該公司的核心平台整合了專有的基因寫入能力以及已建立的基因編輯工具，如 CRISPR–Cas9。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Sana Biotechnology</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Sana Biotechnology</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=SANA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sana Biotechnology Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Sana Biotechnology 嗎？</h2>
</div><p>Before you consider Sana Biotechnology, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Sana Biotechnology 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Sana Biotechnology 並不在名單上。</p>
</div><p>While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Sana Biotechnology 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

HC Wainwright 發佈了對 Sana Biotechnology 收益的樂觀預估